Drug intelligence / Profile preview

Revilife

Development stage: Preclinical
Lead developer: Revive MD

Overview

Revilife is a low-glycemic index (GI) enteral nutrition formula. It is being investigated for its effects on glycemia in individuals with diet-controlled Type 2 Diabetes. The formula is designed to provide nutritional support while helping to manage blood glucose levels.

Brand names: Revilife
Other names: 力存

Beyond the preview

Go deeper on Revilife.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revilife.

Explore the full profile